Full-Time

Director – GMP Operational Quality

Updated on 3/14/2025

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$182.4k - $273.5kAnnually

+ Bonus + Equity Awards

Senior, Expert

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

This is a hybrid-eligible role, allowing for up to two days of remote work per week.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Risk Management
Requirements
  • Strong leadership skills with the ability to thrive in a high throughput environment
  • Project Management / Continuous Improvement
  • Ability to lead and manage projects/teams within corporate objectives and project timelines
  • Proficient in utilizing project management processes/tools to lead meetings, assist with project planning, and facilitate completion of tasks
  • Demonstrated ability to work independently to provide QA support for large, multifaceted projects
  • Collaboration / Teamwork / Conflict Management
  • Ability to independently lead cross-functional teams and represent the Quality unit
  • Ability to understand and translate business needs
  • Recognized as a mentor with a strong ability to transfer technical knowledge and teach skills to junior staff
  • Represents Vertex Commercial Quality Assurance on cross-functional working teams and is recognized for strong communication and influencing skills
  • Critical Thinking / Problem Solving
  • Ability to evaluate quality matters and make decisions utilizing a risk-based approach
  • Flexibility/Adaptability
  • Attention to detail
  • Expert knowledge of global GMP requirements governing oral drug products and knowledge of oral drug product manufacturing practices
  • GMP/GDP regulations and application to Manufacturing and Testing risk management principles
  • Root Cause Analysis tools/methodology
  • Audit process
  • Broad GxP Knowledge and understanding across the lifecycle of the product
  • Sense of urgency and priority- the ability to act quickly/escalation process/transparency
Responsibilities
  • Led the Quality Operations group primarily responsible for providing quality oversight and support to the Vertex Manufacturing Center (VMC) Facility operation in the following key areas/activities; support of manufacturing operations across all phases of development and commercial, support of analytical laboratory operations, and material management including engineering, validation/qualification, and facilities/utilities.
  • Provides strategic leadership, to achieve the corporate and strategic goals to support clinical and commercial manufacturing, continuous improvements, and maintain the inspection readiness state of the facility
  • Enables strategic enhancements in alignment with the Senior Quality Leadership Team.
  • Provide operational strategies to address compliance gaps or determine enhancements to cross-functional quality systems
  • Directs teams responsible for internal quality commercial and development operations in support of GMP manufacturing and testing activities, including disposition responsibilities of material produced internally at Vertex.
  • Participates in cross-functional projects in a Quality expert role.
  • Provides operational strategies to address compliance gaps.
  • May be required to assist with commercial and clinical batch disposition activities. Review batch data, including batch records, deviations, QC release testing, and other quality systems as applicable to determine the acceptability of product disposition.
  • Provide QA support for development and commercial change controls, GMP investigations, associated CAPAs, and Effectiveness Checks.
  • Responsible for monitoring and tracking key metrics, and trends; and proposing solutions as needed.
  • Lead/assist compliance walkthroughs of the site and help drive the closure of any observations.
  • Act as a trusted advisor to the site by providing compliance guidance through collaborative review and working with the business owners to gain a better understanding of their needs and facilitate resolution of quality issues on time.
  • Responsible for providing QA oversight of internal process and cleaning validation activities and evaluation of process being in a state of control.
  • Responsible for review/approval of validation protocols and reports
  • Participate in inspection readiness activities and provide support during regulatory site inspections. Provide post-inspection support to address any regulatory observations.
  • Responsible for workforce planning/resource modeling and updating through forecasting activities.
Desired Qualifications
  • Master’s degree in a relevant field and 5 – 8 years of relevant work experience, or
  • Bachelor's degree in a scientific or allied health field (or equivalent degree)
  • 10+ years of experience, or the equivalent combination of education and experience.
  • Experience with drug product (oral solid dosage forms preferred) development and manufacturing with proficient knowledge of the following in a pharmaceutical setting: CGMP’s and associated CMC regulatory considerations
  • Experience with equipment, facilities, and utility system qualifications activities in a CGMP setting
  • Experience successfully leading event investigations, Root Cause Analysis (RCA), CAPA, QbD, QRM
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Orna Therapeutics enhances Vertex's gene-editing capabilities.
  • Strong investor confidence shown by recent investments from JSF Financial and Channel Wealth.
  • Vertex's non-opioid pain therapies address the opioid crisis, offering market opportunities.

What critics are saying

  • Vertex is under investigation for potential securities law violations.
  • Mixed Phase II data for suzetrigine may delay its development timeline.
  • $1.07 billion investment in Orna partnership poses financial risk if outcomes fall short.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic biotech partnerships.
  • Vertex's innovative gene-editing therapies target unmet medical needs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

GlobeNewswire
Mar 18th, 2025
Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investors Financing extends Arbor’s cash runway into...

MarketBeat
Feb 14th, 2025
JSF Financial LLC Invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

JSF Financial LLC invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

MarketBeat
Jan 17th, 2025
Channel Wealth LLC Invests $716,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Channel Wealth LLC invests $716,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Zenopa
Jan 8th, 2025
Vertex and Orna Partner for Innovative Gene Therapy Solutions

In a significant advancement for the biopharma industry, Vertex Pharmaceuticals has announced a partnership with Orna Therapeutics to develop cutting-edge in vivo gene editing therapies targeting sickle cell disease and beta thalassaemia.

Pipeline Review
Jan 8th, 2025
Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

We look forward to partnering with Vertex to develop transformative therapies for SCD and TDT, while simultaneously advancing our lead panCAR(TM) pipeline programs in autoimmune and oncology.